The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
Bayer AG's corporate venture arm has invested more than €1.3bn since 2015 and intends to match that sum from now through 2024 to support biotechs developing innovative technologies in healthcare.
At the German major's first 'breakthrough innovation forum' on 1 April, outlining the company's long-term plans in pharma and agriculture,...
Create an account to read this article
Already a subscriber?
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.
